Champions Oncology
CSBR
45 hedge funds and large institutions have $47.2M invested in Champions Oncology in 2018 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 14 increasing their positions, 11 reducing their positions, and 6 closing their positions.
150% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 6
27% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 11
22% more funds holding
Funds holding: 37 → 45 (+8)
1.17% more ownership
Funds ownership: 51.44% → 52.61% (+1.2%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
53% less capital invested
Capital invested by funds: $100M → $47.2M (-$52.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Cadence Capital Management
Boston,
Massachusetts
|
+$1.41M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$798K |
| 3 |
Allianz Asset Management
Munich,
Germany
|
+$743K |
| 4 |
Bank of New York Mellon
New York
|
+$603K |
| 5 |
Invesco
Atlanta,
Georgia
|
+$596K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$2.16M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$748K |
| 3 |
VF
Virtu Financial
New York
|
-$642K |
| 4 |
GIP
Granite Investment Partners
El Segundo,
California
|
-$427K |
| 5 |
OC
Oppenheimer & Co
New York
|
-$344K |
CSBR Hedge Fund Activity: Q4 2018 in Review
45 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Champions Oncology (CSBR) for Q4 2018, worth a combined $47.2M — down 53% from $100M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new CSBR positions and 6 closed out — a net gain of 9 holders — while 14 added to existing stakes and 11 trimmed.
The largest buyer was Cadence Capital Management, opening a new position worth an estimated $1.41M. The largest seller was JP Morgan Chase, exiting entirely with an estimated $2.16M sold.
- 45 institutional investors held Champions Oncology (CSBR) as of Q4 2018, up from 37 in Q3 2018.
- Funds reported $47.2M of Champions Oncology stock for Q4 2018, down 53% quarter-over-quarter.
- 15 funds opened new Champions Oncology positions in Q4 2018 and 6 closed out, a net change of +9 holders.
- The largest Champions Oncology buyer in Q4 2018 was Cadence Capital Management, an estimated $1.41M added.
- The largest Champions Oncology seller in Q4 2018 was JP Morgan Chase, an estimated $2.16M sold.
Based on aggregated 13F filings for Q4 2018.